Post investment, the company holds 99.96% of the total share capital of ZIMTAS

The incorporation of Wholly owned subsidiary is with an objective of expansion and development of business in the LATAM region

This approval strengthens ZIM’s presence in the pain management and gastro-protective therapeutic areas

The Board of Directors of the company in their meeting held on August 07, 2025, has approved the same

This achievement aligns with ZIM’s strategy to leverage its development and manufacturing expertise to build a robust pipeline of differentiated generics for global markets

This milestone reflects ZIM’s continued focus on differentiated, technology-driven generics designed to improve treatment adherence and patient experience

Post investment, the shareholding of the ZIM FZE remains at 100% of the total share capital of ZIM SO

Post investment, the shareholding of the company remains at 100% of the total share capital of SIA ZIM Laboratories

Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by the company

This authorisation will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities

With this, the newly incorporated subsidiary become step-down subsidiary of the Company

The Board of Directors in their meeting held on September 30, 2024 have considered and inter alia approved the same

The company has received the license from Dubai Multi Commodities Center for commencement of business

These initiatives signify the company’s growth plans and its aim to introduce innovative products for expansion across new markets

The company’s wholly owned European Subsidiary executed an agreement with one of the European partner for transfer of the marketing authorization

The company is already listed on the BSE since June 2018, will now extend its listing to the NSE